We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The WHO said this decision does not apply to the use or evaluation of hydroxychloroquine as a prophylaxis treatment in people exposed to COVID-19. Read More
A majority of European clinical trials of COVID-19 drugs are being run by universities and companies who either lack experience or have a poor track record in uploading their results to the EU’s trial database, which could lead to wasted research, according to a new report. Read More
A small study of early COVID-19 patients in Italy showed Roche’s Actemra (tocilizumab) provided no benefit, the Italian Medicines Agency (AIFA) said. Read More
Sponsors of trials impacted by the COVID-19 pandemic have several statistical analysis options for mitigating the effect of missing data, according to the FDA. Read More
Chinese government-owned vaccine developer Sinopharma says its COVID-19 vaccine candidate has generated a 100 percent antibody response in patients who were given two medium doses 28 days apart. Read More
CureVac has won approval in Germany and Belgium for a phase 1 trial of its COVID-19 vaccine, just days after the German government announced it was acquiring a 23 percent stake in the company. Read More
Regulators, drugmakers and researchers need to work in parallel to speed development of COVID-19 vaccines and treatments and prepare for the hurdles still to come, a former FDA commissioner advised. Read More
The results suggest that one death would be prevented for every eight ventilated patients treated and one in every 25 for patients receiving oxygen alone. Read More
The University of Oxford’s RECOVERY trial has found that a cheap and widely available steroid provides a benefit in COVID-19 patients and should become standard of care in patients sick enough to require oxygen. Read More